10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Rating of "Hold" from Analysts

Shares of 10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) have been assigned a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.79.

A number of analysts have recently weighed in on TXG shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a report on Tuesday, April 8th. Canaccord Genuity Group cut their target price on 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Citigroup lowered their price target on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Stifel Nicolaus reduced their price objective on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th.

10x Genomics Stock Down 1.3 %

Shares of NASDAQ:TXG traded down $0.11 during trading on Thursday, reaching $8.16. 3,053,746 shares of the company traded hands, compared to its average volume of 2,180,986. The firm has a market capitalization of $997.98 million, a PE ratio of -5.37 and a beta of 2.01. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $32.18. The company's 50 day moving average is $10.18 and its two-hundred day moving average is $13.76.

Remove Ads

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, research analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares of the company's stock, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is owned by company insiders.

Institutional Trading of 10x Genomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. lifted its position in shares of 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after purchasing an additional 943 shares during the period. Blue Trust Inc. lifted its holdings in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC boosted its position in 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after acquiring an additional 1,330 shares during the last quarter. Signaturefd LLC grew its holdings in 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after acquiring an additional 1,452 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after acquiring an additional 1,614 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.